FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

Brain metastasis is a devastating problem in patients with breast, lung and melanoma tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, we performed a multicenter study includ...

ver descrição completa

Detalhes bibliográficos
Autores: Martínez Aranda, Antonio, Hernández, Vanessa, Guney, Emre|||0000-0002-3466-6535, Muixí, Laia, Foj, Rubén, Baixeras, Núria, Cuadras, Daniel|||0000-0001-8780-1764, Morros, Rosa|||0000-0001-6752-8748, Urruticoechea, Ander|||0000-0003-0359-3641, Gil, Miguel, Oliva Miguel, Baldomero|||0000-0003-0702-0250, Moreno, Ferran, González Suarez, Eva, Vidal, Noemí|||0000-0002-2852-6667, Andreu, Xavier, Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746, Ballester Alabau, Rosa María, Castellà Fernández, Eva, Sierra-Jimenez, Angels|||0000-0003-1023-3492
Formato: artículo
Fecha de publicación:2015
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:163248
Acesso em linha:https://ddd.uab.cat/record/163248
https://dx.doi.org/urn:doi:10.18632/oncotarget.5471
Access Level:acceso abierto
Palavra-chave:Marcadors bioquímics
FN14
GRP94
Biomarkers
Brain metastasis
Breast cancer
Descrição
Resumo:Brain metastasis is a devastating problem in patients with breast, lung and melanoma tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, we performed a multicenter study including 318 patients with breast carcinomas. Among these patients, there were 138 patients with metastasis, of whom 84 had brain metastasis. The likelihood of developing brain metastasis increased by 5.24-fold (95%CI 2.83-9.71) and 2.55- (95%CI 1.52-4.3) in the presence of FN14 and GRP94, respectively. Moreover, FN14 was more sensitive than ErbB2 (38.27 vs. 24.68) with similar specificity (89.43 vs. 89.55) to predict brain metastasis and had identical prognostic value than triple negative patients (p 0.0001). Furthermore, we used GRP94 and FN14 pathways and GUILD, a network-based disease-gene prioritization program, to pinpoint the genes likely to be therapeutic targets, which resulted in FN14 as the main modulator and thalidomide as the best scored drug. The treatment of mice with brain metastasis improves survival decreasing reactive astrocytes and angiogenesis, and down-regulate FN14 and its ligand TWEAK. In conclusion our results indicate that FN14 and GRP94 are prediction/prognosis markers which open up new possibilities for preventing/treating brain metastasis.

Registos relacionados